drugset / Trial / NCT01547598

Safety and Efficacy of LUMIGAN® RC Versus DuoTrav® in Patients Who Require Further Intraocular Pressure (IOP) Reduction

NCT01547598

Phase 4 Completed 135 enrolled Allergan
RandomizedParallel-groupSingle-blindTreatment

Summary

This non-inferiority study will assess safety and efficacy of LUMIGAN® RC (bimatoprost ophthalmic solution 0.01%) versus DuoTrav® (travoprost 0.004%/timolol 0.5% combination ophthalmic solution) in patients previously on Travatan® Z (travoprost ophthalmic solution 0.004%) monotherapy.

Timeline

Start
2011-12
Primary completion
2013-07
Completion
2013-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator Bimatoprost Other / unclassified 0.01 % Other
Comparator Timolol Other / unclassified 0.5 % Other
Comparator Travoprost Other / unclassified 0.004 % Other